Search

AZD7442

AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

MK-0668

Solcoseryl

GC-373

Along with its prodrug, GC-376, GC-373 was recently investigated _in vitro_ in cell culture against SARS-Cov-2 M^pro [A219036]. … GC-373 has been shown to inhibit the M^pro target in various coronavirus strains, including feline, mink, and ferret M^pro [A219041].

Mycobacterium w. Vaccine

The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. … It has protective efficacy against M. tuberculosis and M. leprae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

VA-MENGOC-BC®

VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. … As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C.

CIGB 2020 Vaccine

CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. … As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.

BacTRL-spike

As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids.

Potassium aspartate